The treatment landscape for colorectal cancer is based on chemotherapies and targeted agents, although the latter (e.g., Avastin, Erbitux, Vectibix) are currently confined to the metastatic setting. The 2017 FDA approvals of the PD-1 inhibitors Keytruda and Opdivo for MSI-H or dMMR metastatic colorectal cancer have heralded the entry of immunotherapy for this biomarker-defined patient population. This content investigates medical oncologists’ current prescribing practices for colorectal cancer in the United States and analyzes the key factors that drive treatment decisions.
- What is the uptake of Keytruda and Opdivo for previously treated MSI-H/dMMR metastatic colorectal cancer in the United States?
- What is the patient share of key therapies used to treat RAS wild-type and RAS-mutant metastatic colorectal cancer?
- What drivers and obstacles influence treatment decisions in the metastatic setting for select targeted therapies?
- How do drug-treatment rates vary between key colorectal cancer patient segments, according to biomarker status and line of therapy?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that companies can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 101 medical oncologists in the United States fielded in April 2018.
Key companies: Roche/Genentech, Eli Lilly, Amgen, Taiho Pharmaceutical, Merck & Co., Bristol-Myers Squibb, Sanofi, Regeneron, Bayer HealthCare
Key drugs: Avastin, Erbitux, Vectibix, Lonsurf, Keytruda, Opdivo, Stivarga, Cyramza, Zaltrap